![Quiver Logo](/static/img/logo-icon.png)
![AEZS logo](https://quiver-logos.s3.us-east-2.amazonaws.com/aezs.png)
Aeterna Zentaris, Inc.
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna's lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AEZS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of AEZS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AEZS's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to AEZS
Recent picks made for AEZS stock on CNBC
ETFs with the largest estimated holdings in AEZS
Flights by private jets registered to AEZS
![Quiver Logo](/static/img/logo-icon.png)